youtube_live
Q3 2026 earnings • in 4 days
See detailschevron_right
ASND:NASDAQ
Ascendis Pharma A/S
$256.82
arrow_upward
+1.33%(+3.37) 1D
$256.82
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 6, 4:00:01 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ASND...
Open
$253.45
High
$258.46
Low
$251.02
Mkt. cap
17.05B
Avg. vol.
683.12K
Volume
883.85K
P/E ratio
20.75
52-wk high
$282.15
52-wk low
$188.07
EPS
$12.38
Shares outstanding
62.38M
No. of employees
1K
Open
$253.45
High
$258.46
Low
$251.02
Mkt. cap
17.05B
Avg. vol.
683.12K
Volume
883.85K
P/E ratio
20.75
52-wk high
$282.15
52-wk low
$188.07
EPS
$12.38
Shares outstanding
62.38M
No. of employees
1K
News stories
From web sources and news partners
Investing.com
·
1 day ago
Ascendis Pharma’s TransCon CNP maintains orphan drug status in EU
Yahoo! Finance Canada
·
2 days ago
Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
About Ascendis Pharma A/S
CEO-
Employees1.19K
Founded2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteascendispharma.com
Analyst ratings
Based on 18 analysts giving stock ratings to ASND in the past 3 months
Strong buy
Buy
17
Hold
1
Sell
0
12-month forecast
Based on 18 Wall Street analysts offering 12 month price targets for ASND in the last 3 months.
Highest
Current $256.82
$344.00 (+33.95%)
Average
$310.69 (+20.98%)
Lowest
$268.00 (+4.35%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Sean Laaman Morgan Stanley | Buy | Reiterated | $273.00 | +6.3% | 11/02/2026 |
Gary Nachman Canaccord Genuity | Hold | Initiated | $268.00 | +4.4% | 10/26/2026 |
Eric Joseph Citi | Buy | Maintained | $330.00 | +28.5% | 10/26/2026 |
Mitchell Kapoor H.C. Wainwright | Buy | Reiterated | $344.00 | +33.9% | 10/19/2026 |
Joon Lee UBS | Buy | Initiated | $269.00 | +4.7% | 10/16/2026 |
Maxwell Skor Morgan Stanley | Buy | Reiterated | $273.00 | +6.3% | 10/12/2026 |
Jessica Fye J.P. Morgan | Buy | Reiterated | - | - | 10/10/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Reiterated | - | - | 10/09/2026 |
Luca Issi RBC Capital | Buy | Maintained | $290.00 | +12.9% | 10/08/2026 |
Eliana Merle Barclays | Buy | Maintained | $329.00 | +28.1% | 09/30/2026 |
Li Watsek Cantor Fitzgerald | Buy | Maintained | $300.00 | +16.8% | 09/25/2026 |
Yun Zhong Wedbush | Buy | Maintained | $327.00 | +27.3% | 09/16/2026 |
David Lebowitz BMO Capital | Buy | Maintained | $319.00 | +24.2% | 09/14/2026 |
Martin Auster Raymond James | Buy | Maintained | $287.00 | +11.8% | 09/15/2026 |
Leland Gershell Oppenheimer | Buy | Maintained | $312.00 | +21.5% | 09/02/2026 |
Alex Thompson CFA Stifel Nicolaus | Buy | Maintained | $326.00 | +26.9% | 09/01/2026 |
Unknown Analyst Oppenheimer | Buy | Maintained | $312.00 | +21.5% | 09/02/2026 |
Faisal Khurshid Jefferies | Buy | Maintained | $330.00 | +28.5% | 08/31/2026 |
Evan Seigerman BMO Capital | Buy | Initiated | $319.00 | +24.2% | 08/18/2026 |
Unknown Analyst BMO Capital | Buy | Initiated | $319.00 | +24.2% | 08/18/2026 |
Derek Archila Wells Fargo | Buy | Maintained | $326.00 | +26.9% | 08/14/2026 |
Yaron Werber TD Cowen | Buy | Maintained | $341.00 | +32.8% | 08/13/2026 |
Gavin Clark-Gartner Evercore ISI | Buy | Maintained | $329.00 | +28.1% | 08/07/2026 |
Paul Choi Goldman Sachs | Buy | Maintained | $300.00 | +16.8% | 07/27/2026 |
Joseph Schwartz Leerink Partners | Buy | Reiterated | $305.00 | +18.8% | 06/02/2026 |
Unknown Analyst J.P. Morgan | Buy | Maintained | $295.00 | +14.9% | 05/20/2026 |
Unknown Analyst Citi | Buy | Initiated | $355.00 | +38.2% | 05/15/2026 |
Unknown Analyst Evercore ISI | Buy | Maintained | $324.00 | +26.2% | 04/13/2026 |
Next call in 4 days
Thu, Nov 12, 3:00 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (EUR)
- GAAP EPS / Est. (EUR)
- / €1.12
Revenue / Est. (EUR)
- / 364.73M
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in EUR | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 213.63M | 247.50M | 246.60M | 339.28M |
Cost of goods sold | 22.35M | 23.60M | 17.52M | 27.66M |
Cost of revenue | 22.35M | 23.60M | 17.52M | 27.66M |
Research and development expenses | 66.88M | 82.20M | 59.04M | 75.89M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 113.40M | 139.31M | 145.23M | 173.34M |
Operating expense | 180.28M | 221.51M | 204.27M | 91.16M |
Total operating expenses | 202.64M | 245.11M | 221.79M | 118.82M |
Operating income | 11.00M | 2.39M | 24.81M | 220.46M |
Other non operating income | - | -105.57M | - | - |
EBT including unusual items | -57.37M | -26.70M | -48.18M | 230.09M |
EBT excluding unusual items | -57.37M | -34.21M | -48.18M | 230.09M |
Income tax expense | 3.62M | 6.86M | -677.52M | 23.12M |
Effective tax rate | -6.30% | -25.68% | 1,406.31% | 10.05% |
Other operating expenses | - | - | - | -158.07M |
Net income | -60.99M | -33.56M | 629.34M | 206.97M |
Net profit margin | -28.55% | -13.56% | 255.21% | 61.00% |
Earnings per share | -1.00 | -0.55 | 0.27 | 0.90 |
Interest and investment income | 6.04M | 64.06M | 4.52M | 19.96M |
Interest expense | -66.90M | -74.65M | -67.26M | -14.17M |
Net interest expenses | -60.87M | -10.59M | -62.74M | 5.79M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 15.02M | 3.60M | 29.03M | 225.03M |
Gain or loss from assets sale | - | - | - | 21.00K |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events